What is Lifesci Capital’s Estimate for DBVT Q2 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT) – Equities research analysts at Lifesci Capital issued their Q2 2025 EPS estimates for DBV Technologies in a report released on Thursday, June 26th. Lifesci Capital analyst S. Slutsky anticipates that the company will earn ($0.13) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. Lifesci Capital also issued estimates for DBV Technologies’ Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.62) EPS and FY2026 earnings at ($0.29) EPS.

A number of other brokerages have also recently issued reports on DBVT. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Tuesday, May 27th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, May 9th. HC Wainwright raised their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, May 5th. The Goldman Sachs Group upgraded shares of DBV Technologies to a “sell” rating and set a $7.25 price target for the company in a research report on Thursday, May 29th. Finally, JMP Securities reiterated a “market outperform” rating and set a $21.00 price target on shares of DBV Technologies in a research note on Thursday, June 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.75.

DBV Technologies Price Performance

NASDAQ DBVT opened at $9.16 on Monday. The company has a fifty day moving average of $9.25 and a two-hundred day moving average of $6.36. The company has a market capitalization of $250.89 million, a PE ratio of -1.86 and a beta of -0.63. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $12.78.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative return on equity of 278.24%. The company had revenue of $0.51 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.